WO 2005/085250

101

CLAIMS

1. A compound of formula (I):

5 PBD-A-Y-X-(Het)_{na}-L-(Het)_{nb}-L-(Het)_{nc}-T-(Het')_{nd}-L-(Het')_{ne}-L-(Het')_{ne}-X'-Y'-A'-PBD' (T)

and salts, solvates, chemically protected forms, and prodrugs thereof, wherein

with the bonds at the 8 position on each molecule bond to the A and A' groups respectively.

the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;

 \mathbb{R}^2 and \mathbb{R}^3 are independently selected from -H, -OH, =O, =CH₂, -CN,

15 -R, OR, halo, =CH-R, O-SO₂-R, CO₂R and COR;

carbonyl group;

- R^6 , R^7 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo; where R and R' are independently selected from optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups; or
- 20 R^6 and R^7 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2; R^{10} is a nitrogen protecting group and R^{15} is either $O-R^{11}$, where R^{11} is a hydroxyl protecting group; or R^{15} is OH, =O or =S; or

R10 and R15 together form a double bond between C10 and N11;

25 A is selected from O, S, NH or a single bond;
Y is a divalent group such that HY = R, or a single bond;
X and X' are both either NH or C(=0);
each Het and Het' is independently an amino-heteroarylene-

30 each L is independently selected from β -alanine, glycine, 4-aminobutanoic acid and a single bond;

WO 2005/085250

102

T is a divalent linker group of the form:

$$-NH-Q-NH-$$
 or $-C$ (=O) $-Q-C$ (=O) $-$

wherein Q is a divalent group such that HQ = R; A', Y', Het', $R^{2'}$, $R^{3'}$, $R^{6'}$, $R^{7'}$, $R^{9'}$, $R^{10'}$, $R^{11'}$ and $R^{15'}$ are all independently selected from the same lists as previously defined for A, Y, Het, R^2 , R^3 , R^6 , R^7 , R^9 , R^{10} , R^{11} and R^{15} respectively; na, nb, nc, nd, ne and nf are each independently 0 to 5 and the sum na + nb + nc + nd + ne + nf is 0 to 16.

- 10 2. A compound according to claim 1, wherein the sums na + nb + nc and nd + ne + nf are equal.
 - 3. A compound according to either claim 1 or claim 2, wherein Het and Het' are nitrogen containing heteroarylene units.
 - 4. A compound of formula (II):

15

PBD-A-Y-X-(Het)
$$_{ng}$$
-[L-(Het) $_{nh}$] $_{nj}$ -X'-Y'-A'-PBD'

20 and salts, solvates, chemically protected forms, and prodrugs thereof, wherein

the bonds at the 8 position on PBD and PBD' bond to A and A' groups respectively;

- 25 the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3;
 - R^2 and R^3 are independently selected from -H, -OH, =O, =CH₂, -CN, -R, OR, halo, =CH-R, O-SO₂-R, CO₂R and COR;
- R^6 , R^7 and R^9 are independently selected from H, R, OH, OR, SH,
- 30 SR, NH2, NHR, NRR', nitro, Me $_3$ Sn and halo; where R and R' are

WO 2005/085250 PCT/GB2005/000767

103

independently selected from optionally substituted C_{1-7} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups; or

 R^6 and R^7 together form a group $-O-(CH_2)_p-O-$, where p is 1 or 2; R^{10} is a nitrogen protecting group and R^{15} is either $O-R^{11}$, where

5 R¹¹ is a hydroxyl protecting group; or

 R^{15} is OH, \doteq O or =S; or

35

н.

 ${\bf R^{10}}$ and ${\bf R^{15}}$ together form a double bond between C10 and N11; A is selected from O, S, NH or a single bond;

Y is a divalent group such that HY = R, or a single bond;

- 10 each Het is independently an amino-heteroarylene-carbonyl group; each L is independently selected from β -alanine, glycine, 4-aminobutanoic acid and a single bond;
 - A', Y', R^2 ', R^3 ', R^6 ', R^7 ', R^9 ', R^{10} ', R^{11} ' and R^{15} ' are all independently selected from the same lists as previously defined
- for A, Y, Het, R^2 , R^3 , R^6 , R^7 , R^9 , R^{10} , R^{11} and R^{15} respectively; ng is 1 to 5, nh is 1 to 5 and nj is 0 to 3 X and X' are either NH and C(=0) respectively or C(=0) and NH respectively.
- 20 5. A compound according to claim 4, wherein the total number of Het groups in the compound represented by the sum $ng + (nj \times nh)$) is 1 to 3.
- 6. A compound according to either claim 4 or claim 5, wherein 25 Het are nitrogen containing heteroarylene units.
 - 7. A compound according to any one of the preceding claims, wherein PBD and PBD' are the same.
- 30 8. A compound according to any one of the preceding claims, wherein R^9 and $R^{9'}$ are H.
 - 9. A compound according to any one of the preceding claims, wherein R^2 , R^3 , R^{2^\prime} and R^{3^\prime} are independently selected from R and

WO 2005/085250

PCT/GB2005/000767

104

- 10. A compound according to any one of the preceding claims, wherein R^6 and $R^{6\prime}$ are independently selected from H, OH, OR, SH, NH₂, nitro and halo.
- 5 11. A compound according to any one of the preceding claims, wherein R^7 and $R^{7'}$ are independently selected from H, OR, SH, SR, NH₂, NHR, NRR' and halo.
- 12. A compound according to any one of the preceding claims, wherein R^{10} and R^{15} together form a double bond between N10 and C11 and $R^{10'}$ and $R^{15'}$ together form a double bond between N10' and C11'.
- 13. A compound according to any one of claims 1 to 11, wherein R^{10} and R^{10} are independently selected from H, BOC, Troc and alloc, and R^{11} and R^{11} are independently selected from OH, THP or a silyl oxygen protecting group.
- 14. A compound according to any one of claims 1 to 13 for use in20 a method of therapy.
 - 15. A pharmaceutical composition containing a compound of any one of claims 1 to 13, and a pharmaceutically acceptable carrier or diluent.

25

- 16. Use of a compound according to any one of claims 1 to 13 in the manufacture of a medicament for treating a proliferative disease.
- 30 17. A method of treatment of a proliferative disease, comprising administering to a subject in need of treatment a therapeutically-effective amount of a compound of any one of claims 1 to 13.